mRNA Sequencing
Sequence identity is determined for mRNA raw materials and final products (vaccines and therapeutics) using Sanger sequencing following reverse transcription. The obtained sequence is subsequently compared with the respective reference sequence.
Product-specific methods are validated in accordance with ICH Q2 (R2), and the validated methods are subsequently implemented for routine testing.


